Steminent has a pipeline of Stemchymal® clinical programs in development ranging from Pre-clinical stage to Phase II clinical trial.

Steminent’s Stemchymal® allogeneic cell therapy R&D program has generated a portfolio of clinical stage therapeutic candidates for multiple diseases including: Phase II; Spinocerebellar Ataxia (PolyQ SCA), Phase I; Osteoarthritis of the Knee, and Phase I: Acute Liver Failure.

steminent website info update 180917.001